Autism Spectrum Disorder (ASD) appears in early childhood and is characterized by persistent deficits in communication and social interaction, as well as restricted interests, repetitive behaviors, and unusual sensory issues. ASD can be idiopathic or syndromic, in the latter case representing one of the many manifestations of a genetic disorder, such as Rett Syndrome. Psychopharmacology cannot directly ameliorate core autistic symptoms, but rather aims at treating comorbid disorders, such as ADHD, sleep disturbances, psychomotor agitation and aggressiveness, seizures, and anxiety. Until the 90s, it was mainly based on typical neuroleptics and tricyclic antidepressants, whereas second generation antipsychotics later became first-line drugs for these same indications. In general, selective serotonin reuptake inhibitors have not proven manageable in ASD patients. Psychostimulants are indeed frequently prescribed, but display slightly reduced efficacy and enhanced potential for side effects and non-compliance. Targeted patients benefit from mood stabilizers and antiepileptic drugs. Experimental drug treatments for ASD mainly include oxytocin and vasopressin, bumetanide, sulphorafane, nutritional supplements, memantine and D-cycloserine. Work performed on syndromic forms, represents an important source of information for experimental therapies of ASD. Knowledge of the mechanisms underlying autism in each single patient, is on the verge of paving the path to personalized drug treatments.

The Psychopharmacology of Autism Spectrum Disorder and Rett syndrome

Antonio Persico
Primo
;
Arianna Ricciardello;Francesca Cucinotta
Ultimo
2019-01-01

Abstract

Autism Spectrum Disorder (ASD) appears in early childhood and is characterized by persistent deficits in communication and social interaction, as well as restricted interests, repetitive behaviors, and unusual sensory issues. ASD can be idiopathic or syndromic, in the latter case representing one of the many manifestations of a genetic disorder, such as Rett Syndrome. Psychopharmacology cannot directly ameliorate core autistic symptoms, but rather aims at treating comorbid disorders, such as ADHD, sleep disturbances, psychomotor agitation and aggressiveness, seizures, and anxiety. Until the 90s, it was mainly based on typical neuroleptics and tricyclic antidepressants, whereas second generation antipsychotics later became first-line drugs for these same indications. In general, selective serotonin reuptake inhibitors have not proven manageable in ASD patients. Psychostimulants are indeed frequently prescribed, but display slightly reduced efficacy and enhanced potential for side effects and non-compliance. Targeted patients benefit from mood stabilizers and antiepileptic drugs. Experimental drug treatments for ASD mainly include oxytocin and vasopressin, bumetanide, sulphorafane, nutritional supplements, memantine and D-cycloserine. Work performed on syndromic forms, represents an important source of information for experimental therapies of ASD. Knowledge of the mechanisms underlying autism in each single patient, is on the verge of paving the path to personalized drug treatments.
2019
978-0-444-64012-3
File in questo prodotto:
File Dimensione Formato  
25-Ch24.pdf

solo gestori archivio

Descrizione: Proof del capitolo
Tipologia: Documento in Pre-print (manoscritto inviato all'editore, precedente alla peer review)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 466.84 kB
Formato Adobe PDF
466.84 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
3146634.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 6.28 MB
Formato Adobe PDF
6.28 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3146634
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 19
  • ???jsp.display-item.citation.isi??? ND
social impact